PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ATTY. DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE STATEMENT R0150C-REG 10/717,260 BY APPLICANT(S) FIRST NAMED INVENTOR Joseph Armstrong Martin **ART UNIT FILING DATE** Page 1 of 2 November 19, 2003 unknown **U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Applicant of Cited Document Date of Publication of Cited Document Pages, Columns, Lines, Where Relevant Passages or Relevant Examiner Initials \* Kind Code<sup>2</sup> Number MM-DD-YYYY Figures Appear (if known) 3,998,807 John G. Moffatt 12-21-1976 Lilia M. Beauchamp 09-18-1990 **A2** 4,957,924 Horrobin, et al. 06-01-1993 **A3** 5,216,142 02-06-2001 Leanna, et al. **A4** 6.184,376 MCH FOREIGN PATENT DOCUMENTS Pages, Columns, Lines. Date of Foreign Patent Document Name of Patentee or Publication of Where Relevant Examiner Cite Applicant of Cited Kind Code5 Cited Document MM-DD-YYYY Passages or Relevant Initials\* No.1 Office<sup>3</sup> Document Number<sup>4</sup> T<sub>6</sub> (if known) Figures Appear 2000 F. Hoffmann-La 12-19-2002 M:C:HWO 02/100415 **A2 B**1 Roche (CH) -----ICN Pharmaceuticals, 06-28-2001 B2 WO 01/45509 **A1** (US) ICN **Pharmaceuticals** 09-20-2001 WO 01/68034 **A2 B3** (US) Novirio Pharmaceuticals. 11-29-2001 WO 01/90121 **A2 B4** Ltd. Et al. (US),(IT) Schering Corp. 04-27-2000 **B5** WO 00/23454 **A1** (US) Norsk Hydro A.S. 10-13-1994 **B6** WO 94/22887 **A1** (NO) 94/24134 **A1** Hoechst AG (DE) 10-27-1994 **B7** WO

٨

Examiner Signature Date Considered 8/17/04

Norsk Hydro A.S.

(NO) The Wellcome

Foundation Ltd.(GB) Medivir Aktiebolag

(SE)

04-15-1993

06-27-1990

11-23-1989

WO

EP

EP

**B8** 

**B9** 

**B10** 

M CH

93/07163

0 375 329

0 343 133

**A1** 

**B1** 

**B1** 

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)			ATTY. DOCKET NO. R0150C-REG	SERIAL NO. 10/717,260					
			FIRST NAMED INVENTOR Joseph Armstrong Martin						
Page 2 of 2			FILING DATE November 19, 2003	ART UNIT unknown					
THER PRIOR ART NON PATENT LITERATURE DOCUMENTS									
Examir er Initials	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
M:c.	BALIMANE, et al., "Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodruc, Valacyclovir," Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298								
2	C2	BEAUCHAMP, et al., "Amino Acid E Chemistry & Chemotherapy, (1992)							
	СЗ	6-Methoxypurine Arabinoside," Antiva 371-378, 3(6)	odrugs of the Varicella-Zoster Antivira viral Chemistry & Chemotherapy, (199	92), pp.					
	C4	3-(hydroxymethyl)but-1-yl]guanine (l Absorption Properties," J. Med. Che	et al., "Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxynethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Properties," J. Med. Chem., (1989), pp 1738-1743, 32						
	C5	HODGE, et al., "Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-4(-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]," Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10).							
	C6	JONES, et al. "Di- and Triester Prod Methoxypurine Arabinoside," J. Med	rugs of the Varicella-Zoster Antiviral A I. Chem, (1992), pp. 56-63, 35.	Agent 6-					
	C7	propoxymethyl)-6-fluoropurine Mono	'Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-hyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of "J. Med. Chem., (1999), pp. 324-328, 42.						
	C8	MAAG, Hans et al., "Synthesis and Methoxynucleosides," J. Med. Chem	n., (1992), pp. 1440-1451, 35						
	C9	MOFFATT, J.G., "Chemical Transfo Nucleoside Analogues, (R. T. Walke pp. 71-164, Plenum Press, New Yor	rmations of the Sugar Moiety of Nucle er, E. De Clercq, & F. Eckstein, eds.), k. (see p. 144)	osides", (1979),					
	C10	NIELSEN, et al., "Human Peptide Tr Opinion, Ther. Patents (2002), pp. 1	ansporters: Therapeutic Applications, 329-1350, 12(9), Ashley Publications	"Expert					
A	C11	PUE, et al., "Pharmacokinetics of Fa Chemotherapy, (1993), pp. 47-55, 4	amciclovir in Man," Antiviral Chemistry , Suppl. 1	&					
M·C	H C12	RUBIO-ALIAGA, et al., "Mammalian Delivery," Trends in Pharmacologica	Peptide Transporters as Targets for la Sciences, (2002), pp. 434-440, 23(9)	Orug					

Examiner Signature		Date Considered	8/	17	104	
	<del></del>					

i. \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.